Skip to main content

Table 2 Tumor response data

From: Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results

Best overall response*

PR

SD

PR + SD

PD

 

N (%)

All patients (n = 21)

5 (24)

8 (38)

13 (62)

8 (38)

MSKCC intermediate risk (n = 15)

4 (19)

7 (33)

11 (52)

4 (19)

MSKCC poor risk (n = 6)

1 (5)

1 (5)

2 (10)

4 (19)

Heng intermediate risk (n = 11)

4 (19)

5 (24)

9 (43)

2 (10)

Heng poor risk (n = 10)

1 (5)

3 (14)

4 (19)

6 (29)

  1. *Restaging scans occurred after five doses of AGS-003 and cycles 2-4 of sunitinib. NOTE: Responses were determined relative to a baseline scan conducted after nephrectomy and completion of one (1) 6-week cycle of sunitinib.
  2. PD = progressive disease; PR = partial response; SD = stable disease.
Back to article page